SHAREHOLDER ALERT: WeissLaw LLP Reminds MXIM and REXN Shareholders About Its Ongoing Investigations

NEW YORK, Aug. 21, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025

(888) 593-4771
stockinfo@weisslawllp.com

Maxim Integrated Products, Inc. MXIM

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Maxim Integrated Products, Inc. MXIM in connection with the proposed acquisition of the company by Analog Devices, Inc. ("ADI").  Under the terms of the merger agreement, MXIM shareholders will be entitled to receive 0.63 shares of ADI common stock for each MXIM share that they own, representing implied per-share merger consideration of $73.09 based upon ADI's August 21, 2020 closing price of $116.02.  If you own MXIM shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://weisslawllp.com/maxim-integrated-products-inc/ 

Rexahn Pharmaceuticals, Inc. REXN

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Rexahn Pharmaceuticals, Inc. REXN in connection with the proposed stock-for-stock merger of the company with privately-held Ocuphire Pharma, Inc. ("Ocuphire").  Under the terms of the acquisition agreement, REXN stockholders will be issued contingent value rights ("CVR") representing the right to receive (i) 90% of payments received by the combined company pursuant to its licensing agreements with BioSense Global LLC and Zhejiang HaiChang Biotechnology Co., Ltd. during the 15-year period after the closing of the merger; and (ii) 75% of the proceeds received by the combined company from the monetization of REXN's existing intellectual property during the 10-year period after the  merger's close.  Upon consummation of the proposed merger, Ocuphire will own at least 85.7% of the newly-combined company, with REXN stockholders owning the remaining 14.3%.  If you own REXN shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/rexahn-pharmaceuticals-inc/

SOURCE WeissLaw LLP